Effects of Rosemary (Rosmarinus officinalis) Leaves Powder And Weight Reducing Diet on Lipid Profile, Glycemic Status And Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease

Phase 2

Recruiting

• Conditions: onalcoholic fatty liver disease.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20120415009472N20
• Lead Sponsor: Vice-chancellor for research Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 December 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Desire to participate in studying and signing consent
Diagnosis of non-alcoholic fatty liver according to criteria of the American Gastroenterology Association (33): Evidence of hepatic steatosis in liver ultrasound (grade 1 to 3 fatty liver), ALT and AST increased than normal (AST> 38 and ALT> 40 for men and more than 31 and 33 for women), the absence of conditions or diseases secondary to hepatic steatosis, including: alcohol consumption, hereditary disorders affecting liver status (hemochromatosis and Wilson's disease), Known autoimmune disease, history of hepatotoxic drugs (methotrexate, aminodarone, tamoxifen, nifedipine, corticosteroids, valproate, and medications) The virus) and non-use of anticoagulant drugs such as aspirin.
Not getting other diseases and chronic and acute liver disorders (hepatitis B, C, etc.), cirrhosis, celiac disease, diabetes, thyroid disorders, cardiovascular, kidney, pulmonary and inflammatory diseases (rheumatism)
BMI in the range of 40-25 Kg / m2
The age range is 20 to 65 years
No use of any nutritional supplements in the past two months
No use of weight-effective drugs over the past two months
Not having a weight loss diet (a decrease of more than 10% of the weight) over the past three months
Do not use drugs and cigarettes
No pregnancy or lactation

Exclusion Criteria

Secondary conditions that lead to hepatic steatosis, including: alcohol consumption, hereditary disorders affecting liver status (hemochromatosis and Wilson's disease), and known autoimmune diseaseOther chronic and acute liver diseases and disorders such as hepatitis, cirrhosis, celiac disease, diabetes, thyroid disorders, cardiovascular, renal, pulmonary and inflammatory diseases (rheumatism)History of taking hepatotoxic drugs (methotrexate, amiodarone, tamoxifen, nifedipine, corticosteroids, valproate and antiviral drugs) as well as anticoagulants such as aspirin
Use of any nutritional supplement in the past two months
Use of weight-loss drugs over the past two months
Having a severe weight loss diet (more than 10% weight loss) over the past three months
smoking
Pregnancy or lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified